Multidisciplinary Melanoma Program
Due to recent advances, patients with melanoma face an increasingly complex array of options for their care. The Multidisciplinary Melanoma Program is for evaluation and initial management of patients newly diagnosed with melanoma. This program includes experts in Surgical Oncology, Medical Oncology and Dermatology, as well as specialists in Radiation Oncology, Mohs Surgery and Dermatopathology when needed, all with expertise and experience with melanoma to form a comprehensive management plan for patients at any stage of disease.
Pigmented Lesions Unit (PLU)
The PLU follows patients at increased risk of melanoma due to mole pattern and personal or family history, and it can provide ongoing surveillance for patients. The physicians stress the importance of patient education awareness of skin changes to aid in the early detection of lesions.
Martin A. Weinstock, M.D., Ph.D.
Professor of Dermatology, Brown University
Professor of Epidemiology, Brown University
Director, Photomedicine and Pigmented Lesions
2013 Lila and Murray Gruber Memorial Cancer Research Award and Lectureship
2010 American Skin Association Achievement Award
2010 American Academy of Dermatology Presidential Citation
2007 Medical All-Star (chosen by Boston Red Sox to honor medical research)
2007 American Academy of Dermatology Astellas Award (for contributions to public health in dermatology through scientific research, first to win this award)
Dr. Robinson-Bostom follows complicated solid organ transplant recipients. Photography, documentation, and management of skin cancers, cutaneous infections, and unique dermatoses seen in this population is emphasized.
Leslie Robinson-Bostom, M.D.
Professor of Dermatology
Director, Division of Dermatopathology
General Dermatology and Dermatopathology
Dr. Leslie Robinson-Bostom, a graduate of SUNY Health Science Center, Brooklyn, NY, interned at Rhode Island Hospital and completed her dermatology residency in the department of dermatology at Brown Medical School. She went on to complete the Brown Medical School dermatopathology fellowship at Roger Williams Medical Center (affiliated with Brown through 1997) and subsequently joined the department of dermatology staff at Brown Medical School. She is board certified in dermatology and dermatopathology. Dr. Robinson-Bostom started the division of dermatopathology at Rhode Island Hospital, organizing the dermatopathology slide library and teaching curriculum for dermatology and pathology residents. Presently, she is the Director of the Division of Dermatopathology and the Director of the Warren Alpert Medical School of Brown University Dermatology Elective. She serves on the Post Graduate Referral Committee, advising medical students interested in pursuing dermatology careers, and is a member of the Medical School Admissions Committee. Her research interests include elastic tissue disorders, ichthyosis, panniculitis and cutaneous manifestations of renal disease. She has published numerous articles on these topics as well as on many other dermatologic conditions. She also has a very active role in the Dermatology Foundation, a national organization which raises funds for dermatology–related research, as a member of the Dermatology Foundation Board of Trustees and as the RI State Chair of the Leader’s Society. Dr Robinson-Bostom’s clinical interests include panniculitis, elastic tissue disease, cutaneous manifestations of end stage renal disease and skin disease in solid organ transplant recipients.
Contact Dermatitis Center
The Contact Dermatitis Center is a regional referral service for evaluating rashes that might be due to contact allergy, and occupational skin problems. Our Center is staffed by four dermatologists who are very experienced in patch testing. Patients are seen only on referral from dermatologists, allergists, and occupational medicine physicians. Typically, patients are seen for a detailed evaluation and then are patch tested the same day. The patches are left on for 48 hours and are removed at home. Patients return the day after removing the patches for interpretation of the tests and if necessary, four days later for delayed reading. Patch testing is painless and involves placing small quantities of each allergen being tested under a “patch”. No needles or pricking of the skin are involved, so even children are cooperative. A detailed report is sent to the referring physician, and all patients receive printed educational material and personal counseling about their positive tests. If you are interested in being patch tested, please contact your dermatologist, allergist, or occupational medicine physician and refer them to the “For Providers” page of our website for instructions and proper form to complete and send to our office.
Lionel Bercovitch, M.D.
Professor of Dermatology
Director, Division of Pediatric Dermatology
Dr. Bercovitch is a graduate of University of Manitoba Medical School in Canada and completed a medical residency at Massachusetts General Hospital and a dermatology residency at Brown Medical School. He is board certified in Dermatology and Pediatric Dermatology. Dr. Bercovitch is currently Director of Pediatric Dermatology at Hasbro Children’s Hospital and the Contact Dermatitis and Occupational Dermatology Unit at Rhode Island Hospital. He is also the staff dermatologist at Brown University Health Services. His clinical interests include pseudoxanthoma elasticum, biomedical ethics in dermatology, dermatologic clinical genetics, and vascular anomalies. He has served as Medical Director of PXE International since its founding in 1995, and is the President of the Rhode Island Dermatologic Society (2012-2013).
Jennie Muglia, M.D.
Associate Professor of Dermatology, Clinician Educator
Director, Division of Dermatology, The Miriam Hospital
General and Pediatric Dermatology
Dr. Muglia graduated cum laude from Bryn Mawr College with a Bachelor of Arts in Biology and Italian and received her medical degree from UMDNJ-New Jersey Medical School. She completed her internship and internal medicine residency at Roger Williams General Hospital (affiliated with Brown through 1997) in Providence, RI followed by a fellowship in immunodermatology and dermatology residency at the University of Colorado School of Medicine in Denver. She is board certified in internal medicine, dermatology and pediatric dermatology. Dr. Muglia is currently the Director of the Division of Dermatology at The Miriam Hospital in Providence as well as the Director of the Dermatopharmacology Unit at Rhode Island Hospital. She also volunteers her time in the Contact Dermatitis clinic at Rhode Island Hospital and holds a weekly pediatric dermatology clinic at Hasbro Children’s Hospital.
She is actively involved in teaching medical students, dermatology residents and primary care residents in her academic practice, outpatient dermatology clinics and on the inpatient dermatology consultation service at Rhode Island and Hasbro Children’s Hospitals. Her clinical research interests include acne, psoriasis, atopic dermatitis, fungal and viral infections of the skin and cutaneous T cell lymphoma.
She is an active member of the Rhode Island Medical Society, serving on the Public Laws Committee and as the dermatology representative to the Rhode Island Medical Society Council.
Hidradenitis Suppurativa (HS) Clinic
Hidradenitis suppurativa (HS), also referred to as acne inversa, is a folliculo-centric, scarring, debilitating inflammatory condition. Our HS clinic, lead by Dr. So Yeon Paek, is dedicated to the care of adult and pediatric patients with HS through medical, laser, and surgical interventions. Dr. Paek specializes in the management of HS and is actively involved with the Hidradenitis Suppurativa Foundation (HSF) to advance our understanding of the disease, increase awareness, and develop new and effective therapeutics for patients suffering with this condition.
So Yeon Paek, MD
Assistant Professor of Dermatology, Clinician Educator
Director, Phototherapy Unit
Dr. Paek graduated from Yale University and received her medical degree from the University of Texas Southwestern Medical School. She completed a clinical research fellowship at the National Institutes of Health, Internal Medicine internship at St. Luke’s-Roosevelt Hospital Center in New York City, and Dermatology residency at Henry Ford Hospital in Michigan. She is the recipient of several awards and honors for research and patient care, including the Women’s Dermatological Society Academic Research Award and the Michael S. Benninger, M.D. Award for excellence as physician, researcher, and teacher at Henry Ford.
Dr. Paek will be joining the faculty of the Department of Dermatology at the Warren Alpert Medical School of Brown University as Assistant Clinical Professor of Dermatology and co-director of the Center for Skin and Musculoskeletal Diseases. Her clinical and research interests include rheumatologic-dermatologic diseases, psoriasis, immune-mediated skin diseases, medical dermatology, biologic and immunosuppressive therapy for cutaneous diseases, general dermatology, photodermatology, and multicultural dermatology.
XTRAC® Velocity Excimer Laser
The XTRAC® Velocity Excimer Laser is an exciting new treatment for psoriasis. The XTRAC® Velocity laser is designed to provide fast, effective relief from dry, itchy and unsightly psoriasis lesions.
Using a carefully focused beam of laser light delivered through an advanced technology light guide device, the XTRAC® Excimer Laser system can treat psoriasis lesions quickly and effectively. The XTRAC® Laser concentrates the light only on the psoriasis lesion, allowing the physician to deliver high doses necessary for rapid clearing while minimizing exposure of health skin.
Who should consider XTRAC® Excimer Laser treatment?
Individuals with mild, moderate, and severe psoriasis that:
- Are unhappy with their current method of treatment
- Have failed previous treatment options
- Are concerned about potential serious side effects of other treatment options
Individual results will vary depending on the body surface affected. Most patients experience significant improvement in as few as 6 to 10 treatments and clearance in 10 to 20 depending on the severity.
If you would like more information on this treatment, call 401-444-7127.
PhotoDynamic Therapy (PDT)
BLU-U® Blue Light Photodynamic Therapy Illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses.
Actinic Keratosis (AKs) is the most common precancer. AKs are rough-textured, dry, scaly patches on the skin that are caused by excessive exposure to ultraviolet light (UV) such as sunlight. AKs are often called “sun spots”. They occur most often on areas such as the face, scalp and ears. They can range in color from skin tones to reddish brown. They can be as small as a pinhead or larger than a quarter. Frequent skin examinations are the key to early detection and prevention.
Levulan® PDT Topical Solution is applied to the AK. The solution is then absorbed by the AK cells where it is converted to a chemical that makes the cells extremely sensitive to light. When the AK cells are exposed to the BLU-U® Blue Light Photodynamic Therapy Illuminator, a reaction occurs which destroys the AK cells.
If you would like more information on this treatment, call 401-444-7127.